The impact of CGRPergic monoclonal antibodies on prophylactic antimigraine therapy and potential adverse events

Taylor and Francis Group, Expert Opinion on Drug Metabolism and Toxicology, p. 1-13, 2021

Journal article published in 2021 by Abimael González-Hernández

Distributing this paper is prohibited by the publisher

Full text: Unavailable

Preprint: archiving forbidden

Postprint: archiving restricted

Upload

Published version: archiving forbidden

Policy details

Data provided by